Skip to main content
Top
Published in: AIDS and Behavior 2/2006

01-03-2006 | Other Research Articles

Additive Deleterious Effects of Methamphetamine Dependence and Immunosuppression on Neuropsychological Functioning in HIV Infection

Authors: Catherine L. Carey, Steven Paul Woods, Julie D. Rippeth, Raul Gonzalez, Robert K. Heaton, Igor Grant, The HIV Neurobehavioral Research Center (HNRC) Group

Published in: AIDS and Behavior | Issue 2/2006

Login to get access

Abstract

Methamphetamine (MA) dependence and HIV infection are independently associated with cerebral dysfunction, especially within frontal-basal ganglia circuits. Recent evidence indicates that MA dependence has an additive effect on neuropsychological (NP) deficits associated with HIV infection. This study extends prior findings by examining the combined effects of MA dependence (MA+) and immunosuppression (i.e., CD4 lymphocyte count <200) on NP functioning in 284 HIV+ individuals. Prevalence of NP impairment was examined in four demographically comparable groups: (1) MA+/CD4 < 200; (2) MA+/CD4 ≥ 200; (3) MA−/CD4 < 200; and (4) MA−/CD4 ≥ 200. Results revealed that both MA dependence and immunosuppression were significant predictors of NP impairment. More importantly, additive effects were evident whereby the MA+/CD4 < 200 group exhibited the highest rate of NP impairment. Findings indicate that MA dependence conveys an additive deleterious impact on NP status in immunosuppressed persons with HIV infection, perhaps reflecting the combined effects of neuropathophysiological mechanisms in fronto-striatal circuits.
Literature
go back to reference American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders (4th ed.). Washington, D.C.: Author. American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders (4th ed.). Washington, D.C.: Author.
go back to reference Ammassari, A., Trotta, M. P., Murri, R., Castelli, F., Narciso, P., Noto, P., Vecchiet, J., D'Arminio Monforte, A., Wu, A. W., Antinori, A., and The AdICoNA Study Group. (2002). Correlates and predictors of adherence to highly active antiretroviral therapy: Overview of published literature. Journal of Acquired Immune Deficiency Syndromes, 31, S123–S127. Ammassari, A., Trotta, M. P., Murri, R., Castelli, F., Narciso, P., Noto, P., Vecchiet, J., D'Arminio Monforte, A., Wu, A. W., Antinori, A., and The AdICoNA Study Group. (2002). Correlates and predictors of adherence to highly active antiretroviral therapy: Overview of published literature. Journal of Acquired Immune Deficiency Syndromes, 31, S123–S127.
go back to reference Basso, M. R., and Bornstein, R. A. (2000). Effects of immunosuppression and disease severity upon neuropsychological function in HIV infection. Journal of Clinical and Experimental Neuropsychology, 22, 104–114.PubMed Basso, M. R., and Bornstein, R. A. (2000). Effects of immunosuppression and disease severity upon neuropsychological function in HIV infection. Journal of Clinical and Experimental Neuropsychology, 22, 104–114.PubMed
go back to reference Beck, A. T. (1987). The Beck Depression Inventory. San Antonio, TX: Psychological Corporation. Beck, A. T. (1987). The Beck Depression Inventory. San Antonio, TX: Psychological Corporation.
go back to reference Chang, L., Ernst, T., Witt, M. D., Ames, N., Gaiefsky, M., and Miller, E. (2002). Relationships among brain metabolites, cognitive function, and viral loads in antiretroviral-naïve HIV patients. NeuroImage, 17, 1638–1648.CrossRefPubMed Chang, L., Ernst, T., Witt, M. D., Ames, N., Gaiefsky, M., and Miller, E. (2002). Relationships among brain metabolites, cognitive function, and viral loads in antiretroviral-naïve HIV patients. NeuroImage, 17, 1638–1648.CrossRefPubMed
go back to reference Cherner, M., Masliah, E., Ellis, R. J., Marcotte, T. D., Moore, D. J., Grant, I., Heaton, R. K., and The HNRC Group. (2002). Neurocognitive dysfunction during life predicts postmortem findings of HIV encephalitis. Neurology, 59, 1563–1567. Cherner, M., Masliah, E., Ellis, R. J., Marcotte, T. D., Moore, D. J., Grant, I., Heaton, R. K., and The HNRC Group. (2002). Neurocognitive dysfunction during life predicts postmortem findings of HIV encephalitis. Neurology, 59, 1563–1567.
go back to reference De Ronchi, D., Faranca, I., Berardi, D., Scudellari, P., Borderi, M., Manfredi, R., and Fratiglioni, L. (2002). Risk factors for cognitive impairment in HIV-1-infected persons with different risk behaviors. Archives of Neurology, 59, 812–818.CrossRefPubMed De Ronchi, D., Faranca, I., Berardi, D., Scudellari, P., Borderi, M., Manfredi, R., and Fratiglioni, L. (2002). Risk factors for cognitive impairment in HIV-1-infected persons with different risk behaviors. Archives of Neurology, 59, 812–818.CrossRefPubMed
go back to reference Ellis, R. J., Childers, M. E., Cherner, M., Lazzaretto, D., Letendre, S., Grant, I., and The HNRC Group (2003). Increased human immunodeficiency virus loads in active methamphetamine users are explained by reduced effectiveness of antiretroviral therapy. Journal of Infectious Diseases, 188, 1820–1826. Ellis, R. J., Childers, M. E., Cherner, M., Lazzaretto, D., Letendre, S., Grant, I., and The HNRC Group (2003). Increased human immunodeficiency virus loads in active methamphetamine users are explained by reduced effectiveness of antiretroviral therapy. Journal of Infectious Diseases, 188, 1820–1826.
go back to reference Fals-Stewart, W. (1993). Neurocognitive defects and their impact on substance abuse treatment. Journal of Addictions and Offender Counseling, 13, 46–57. Fals-Stewart, W. (1993). Neurocognitive defects and their impact on substance abuse treatment. Journal of Addictions and Offender Counseling, 13, 46–57.
go back to reference First, M. B., Spitzer, R. L., Gibbon, M., and Williams, J. B. (1996). Structured Clinical Interview for DSM-IV Axis I Disorders. New York: Biometrics Research Department. First, M. B., Spitzer, R. L., Gibbon, M., and Williams, J. B. (1996). Structured Clinical Interview for DSM-IV Axis I Disorders. New York: Biometrics Research Department.
go back to reference Grant, I., Atkinson, J. H., Hesselink, J. R., Kennedy, C. J., Richman, D. D., Spector, S. A., and McCutchan, J. A. (1987). Evidence for early central nervous system involvement in the acquired immunodeficiency syndrome (AIDS) and other human immunodeficiency virus (HIV) infections. Annals of Internal Medicine, 107, 828–836.PubMed Grant, I., Atkinson, J. H., Hesselink, J. R., Kennedy, C. J., Richman, D. D., Spector, S. A., and McCutchan, J. A. (1987). Evidence for early central nervous system involvement in the acquired immunodeficiency syndrome (AIDS) and other human immunodeficiency virus (HIV) infections. Annals of Internal Medicine, 107, 828–836.PubMed
go back to reference Heaton, R. K., Kirson, D., Velin, R. A., Grant, I., and The HNRC Group. (1994). The utility of clinical ratings for detecting cognitive change in HIV infection. In I. Grant and A. Martin (Eds.), Neuropsychology of HIV infection (pp. 188–206). New York: Oxford University Press. Heaton, R. K., Kirson, D., Velin, R. A., Grant, I., and The HNRC Group. (1994). The utility of clinical ratings for detecting cognitive change in HIV infection. In I. Grant and A. Martin (Eds.), Neuropsychology of HIV infection (pp. 188–206). New York: Oxford University Press.
go back to reference Heaton, R. K., Grant, I., Butters, N., White, D. A., Kirson, D., Atkinson, J. H., McCutchan, J. A., Taylor, M. J., Kelly, M. D., Ellis, R. J., Wolfson, T., Velin, R., Marcotte, T. D., Hesselink, J. R., Jernigan, T. L., Chandler, J., Wallace, M., Abramson, I., and The HNRC Group. (1995). The HNRC 500—Neuropsychology of HIV infection at different disease stages. Journal of the International Neuropsychological Society, 1, 231–251. Heaton, R. K., Grant, I., Butters, N., White, D. A., Kirson, D., Atkinson, J. H., McCutchan, J. A., Taylor, M. J., Kelly, M. D., Ellis, R. J., Wolfson, T., Velin, R., Marcotte, T. D., Hesselink, J. R., Jernigan, T. L., Chandler, J., Wallace, M., Abramson, I., and The HNRC Group. (1995). The HNRC 500—Neuropsychology of HIV infection at different disease stages. Journal of the International Neuropsychological Society, 1, 231–251.
go back to reference Langford, D., Adame, A., Grigorian, A., Grant, I., McCutchan, J. A., Ellis, R. J., Marcotte, T. D., Masliah, E., and The HNRC Group (2003). Selective damage of calbindin immunoreactive neurons in methamphetamine-user HIVE patients. Journal of Acquired Immune Deficiency Syndromes, 15, 467–474. Langford, D., Adame, A., Grigorian, A., Grant, I., McCutchan, J. A., Ellis, R. J., Marcotte, T. D., Masliah, E., and The HNRC Group (2003). Selective damage of calbindin immunoreactive neurons in methamphetamine-user HIVE patients. Journal of Acquired Immune Deficiency Syndromes, 15, 467–474.
go back to reference Loughlin, A., Metsch, L., Gardner, L., Anderson-Mahoney, P., Barrigan, M., and Strathdee, S. (2004). Provider barriers to prescribing HAART to medically-eligible HIV-infected drug users. AIDS Care, 16, 485–500.CrossRefPubMed Loughlin, A., Metsch, L., Gardner, L., Anderson-Mahoney, P., Barrigan, M., and Strathdee, S. (2004). Provider barriers to prescribing HAART to medically-eligible HIV-infected drug users. AIDS Care, 16, 485–500.CrossRefPubMed
go back to reference Martín-García, J., Kolson, D. L., and González-Scarano, F. (2002). Chemokine receptors in the brain: Their role in HIV infection and pathogenesis. AIDS, 16, 1709–1730.CrossRefPubMed Martín-García, J., Kolson, D. L., and González-Scarano, F. (2002). Chemokine receptors in the brain: Their role in HIV infection and pathogenesis. AIDS, 16, 1709–1730.CrossRefPubMed
go back to reference McArthur, J. C., Hoover, D. R., Bacellar, M. A., Miller, E. N., Cohen, B. A., Becker, J. T., Graham, N. M. H., McArthur, J. H., Selnes, O. A., Jacobsen, L. P., Visscher, B. R., Concha, M., Saah, A., and The Multicenter AIDS Cohort Study. (1993). Dementia in AIDS patients: Incidence and risk factors. Neurology, 43, 2245–2252. McArthur, J. C., Hoover, D. R., Bacellar, M. A., Miller, E. N., Cohen, B. A., Becker, J. T., Graham, N. M. H., McArthur, J. H., Selnes, O. A., Jacobsen, L. P., Visscher, B. R., Concha, M., Saah, A., and The Multicenter AIDS Cohort Study. (1993). Dementia in AIDS patients: Incidence and risk factors. Neurology, 43, 2245–2252.
go back to reference Nath, A., Hauser, K. F., Wojna, V., Booze, R. M., Maragos, W., Prendergast, M., Cass, W., and Turchan, J. T. (2002). Molecular basis for interactions of HIV and drugs of abuse. Journal of Acquired Immune Deficiency Syndromes, 31, S62–S69.PubMed Nath, A., Hauser, K. F., Wojna, V., Booze, R. M., Maragos, W., Prendergast, M., Cass, W., and Turchan, J. T. (2002). Molecular basis for interactions of HIV and drugs of abuse. Journal of Acquired Immune Deficiency Syndromes, 31, S62–S69.PubMed
go back to reference Nordahl, T. E., Salo, R., and Leamon, M. (2003). Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition: A review. Journal of Neuropsychiatry and Clinical Neurosciences, 15, 317–325.PubMed Nordahl, T. E., Salo, R., and Leamon, M. (2003). Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition: A review. Journal of Neuropsychiatry and Clinical Neurosciences, 15, 317–325.PubMed
go back to reference Reger, M., Welsh, R., Razani, J., Martin, D. J., and Boone, K. B. (2002). A meta-analysis of the neuropsychological sequelae of HIV infection. Journal of the International Neuropsychological Society, 8, 410–424.CrossRefPubMed Reger, M., Welsh, R., Razani, J., Martin, D. J., and Boone, K. B. (2002). A meta-analysis of the neuropsychological sequelae of HIV infection. Journal of the International Neuropsychological Society, 8, 410–424.CrossRefPubMed
go back to reference Rippeth, J. D., Heaton, R. K., Carey, C. L., Marcotte, T. D., Moore, D. J., Gonzalez, R., Wolfson, T., Grant, I., and The HNRC Group. (2004). Methamphetamine dependence increases risk of neuropsychological impairment in HIV-infected persons. Journal of the International Neuropsychological Society, 10, 1–14. Rippeth, J. D., Heaton, R. K., Carey, C. L., Marcotte, T. D., Moore, D. J., Gonzalez, R., Wolfson, T., Grant, I., and The HNRC Group. (2004). Methamphetamine dependence increases risk of neuropsychological impairment in HIV-infected persons. Journal of the International Neuropsychological Society, 10, 1–14.
go back to reference Simon, S. L., Domier, C. P., Carnell, J., Brethen, P., Rawson, R. A., and Ling, W. (2000). Cognitive impairment in individuals currently using methamphetamine. The American Journal on Addictions, 9, 222–231.CrossRefPubMed Simon, S. L., Domier, C. P., Carnell, J., Brethen, P., Rawson, R. A., and Ling, W. (2000). Cognitive impairment in individuals currently using methamphetamine. The American Journal on Addictions, 9, 222–231.CrossRefPubMed
go back to reference Taylor, M. J., Alhassoon, O. M., Schweinsburg, B. C., Videen, J. S., Grant, I., and The HNRC Group. (2000). MR spectroscopy in HIV and stimulant dependence. Journal of the International Neuropsychological Society, 6, 83–85. Taylor, M. J., Alhassoon, O. M., Schweinsburg, B. C., Videen, J. S., Grant, I., and The HNRC Group. (2000). MR spectroscopy in HIV and stimulant dependence. Journal of the International Neuropsychological Society, 6, 83–85.
go back to reference The National Institute on Drug Abuse (NIDA) research report series. (2002). Methamphetamine abuse and addiction. Bethesda, MD: National Institutes of Health. The National Institute on Drug Abuse (NIDA) research report series. (2002). Methamphetamine abuse and addiction. Bethesda, MD: National Institutes of Health.
go back to reference Wilkinson, G. S. (1993). The Wide Range Achievement Test—Revision 3. Wilmington, DE: Wide Range, Inc. Wilkinson, G. S. (1993). The Wide Range Achievement Test—Revision 3. Wilmington, DE: Wide Range, Inc.
go back to reference Woods, S. P., Rippeth, J. D., Frol, A. B., Hinkin, C. H., Levy, J. K., Ryan, E., Soukup, V. M., Lazzaretto, D., Cherner, M., Marcotte, T. D., Gelman, B. B., Morgello, S., Singer, E. J., Grant, I., and Heaton, R. K. (2004). Interrater reliability of clinical ratings and neurocognitive diagnoses in HIV. Journal of Clinical and Experimental Neuropsychology, 26, 759–778.PubMedCrossRef Woods, S. P., Rippeth, J. D., Frol, A. B., Hinkin, C. H., Levy, J. K., Ryan, E., Soukup, V. M., Lazzaretto, D., Cherner, M., Marcotte, T. D., Gelman, B. B., Morgello, S., Singer, E. J., Grant, I., and Heaton, R. K. (2004). Interrater reliability of clinical ratings and neurocognitive diagnoses in HIV. Journal of Clinical and Experimental Neuropsychology, 26, 759–778.PubMedCrossRef
go back to reference Woody, G. E., Donnell, D., Seage, G. R., Metzger, D., Marmor, M., Koblin, B. A., Buchbinder, S., Gross, M., Stone, B., and Judson, F. N. (1999). Non-injection substance use correlates with risky sex among men having sex with men. Data from HIVNET. Drug and Alcohol Dependence, 53, 197–205.CrossRefPubMed Woody, G. E., Donnell, D., Seage, G. R., Metzger, D., Marmor, M., Koblin, B. A., Buchbinder, S., Gross, M., Stone, B., and Judson, F. N. (1999). Non-injection substance use correlates with risky sex among men having sex with men. Data from HIVNET. Drug and Alcohol Dependence, 53, 197–205.CrossRefPubMed
Metadata
Title
Additive Deleterious Effects of Methamphetamine Dependence and Immunosuppression on Neuropsychological Functioning in HIV Infection
Authors
Catherine L. Carey
Steven Paul Woods
Julie D. Rippeth
Raul Gonzalez
Robert K. Heaton
Igor Grant
The HIV Neurobehavioral Research Center (HNRC) Group
Publication date
01-03-2006
Publisher
Springer US
Published in
AIDS and Behavior / Issue 2/2006
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-005-9056-4

Other articles of this Issue 2/2006

AIDS and Behavior 2/2006 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.